GenomeQuébec

ANNUAL REPORT 2008-2009

VISION

To put genomics at the heart of the scientific and socioeconomic development of Québec.

MISSION

Through partnerships with key players in life sciences on national and international levels, Génome Québec contributes to strengthening the competitiveness of the system for innovation in genomics. The objective is to maximize the socioeconomic impact in Québec, by funding major genomics research initiatives and putting in place the tools necessary for scientific and strategic development in the field.

FOUR STRATEGIC GOALS

- Reinforce the competitiveness of the genomics innovation system in Québec
- Create a thriving environment for the growth of genomics in Québec
- Improve performance
- Strengthen management

CORPORATE INFORMATION

For more information, please contact the Public Affairs and Communications Department at 514 398-0668 or lthibault@genomequebec.com

Head office
Génome Québec
630, boulevard René-Lévesque Ouest, Bureau 2660
Montréal (Québec) H3B 1S6
Phone: 514 398-0668
Fax: 514 398-0883
E-mail: gqinfo@genomequebec.com
www.genomequebec.com

Auditors
KPMG LLP
600, de Maisonneuve Ouest, Bureau 1500
Montréal (Québec) H3A 0A3
www.kpmg.ca

Legal adviser
M^e^ Jean Brunet
Stein Monast, S.E.N.C.R.L
70, rue Dalhousie, Bureau 300
Québec (Québec) G1K 4B2

Génome Canada
150 Metcalfe Street, Suite 2100
Ottawa (Ontario) K2P 1P1
www.genomecanada.ca

Ministère du Développement économique, de l'Innovation et de l'Exportation du Québec
710, Place D'Youville, 3^e^ étage
Québec (Québec) G1R 4Y4
www.mdeie.gouv.qc.ca

McGill University and
Génome Québec Innovation Centre
740, avenue du Docteur-Penfield
Montréal (Québec) H3A 1A4
Phone: 514 398-5715
Fax: 514 398-1790
infoservices@genomequebec.com

Génome Québec and Montreal Heart Institute Pharmacogenomics Centre
5000, rue Bélanger Est
2e étage, Local S-2086
Montréal (Québec) H1T 1C8
Phone: 514 670-7670
Fax: 514 670-7671
info@pgx.ca

Génome Québec and Université de Sherbrooke RNomics Centre
3201, rue Jean-Mignault
Sherbrooke (Québec) J1E 4K8
Phone: 514 398-7211
infoservices@genomequebec.com

Génome Québec and Center hospitalier affilié universitaire régional de Chicoutimi Biobank
305, rue St-Vallier
Chicoutimi (Québec) G7H 5H6
Phone: 514 398-0668, Ext. 236
servicesbiobanque@genomequebec.com

Thanks to our partners

Développement économique, Innovation et Exportation Québec

GenomeCanada

MESSAGE FROM THE CHAIRMAN OF THE BOARD

"We are ready to relaunch our activities with dynamic energy in order to reinforce the competitiveness in innovative genomics and maximize the socio-economic benefits."

In the eight years since Génome Québec was founded, it has generated and managed some $400 million in investments in genomics research, a figure which has grown year after year, at the same success rate as the Québec scientific community. For this reason, the organization needed to expand rapidly and it is important to highlight the excellent work of all those who contributed to the remarkable outcome. However, in 2008-2009, the organization also reached a critical point in its evolution: the moment arrived for us to question the role of Génome Québec. We needed to rethink our business model and our relationships with our partners, as well as re-examine our governance. The process of reflection and restructuring initiated in recent months will continue over the next year. I would like to thank the Génome Québec team and especially, the members of the Board for their commitment to reform.

What will the future hold? Génome Québec is entering the second phase of its history in 2009-2010. Thanks to a new management team which has the full confidence of the Board of Directors, and thanks to an internal consolidation about to be completed, we are ready to relaunch our activities with dynamic energy in order to reinforce the competitiveness in innovative genomics and maximize the socio-economic benefits.

We must, of course, proceed keeping the funding for genomics research in mind. In the current economic crisis, it is very tempting to limit research funding to focus on creating short-term employment. In my opinion, there are other approaches that exist, like those being taken by neighbouring communities. Ontario and the US, for example, suggest that such a crisis can actually draw significant research investments. Essentially, we need to protect our knowledge, retain our research scientists and protect the expertise that allows us to be the frontrunners on a national and international level. As well, while building wealth and employment through innovative ideas, we must ensure that the foundation of economic development is both modern and sustainable. This is the direction we are striving for in the coming months, with the intention of stimulating interest from sponsors and trying to encourage them to renew their support for research in general, and particularly towards that of Génome Québec and our partners, thus promoting our mission.

Jean-Claude Cadieux
Chairman of the Board

MESSAGE FROM THE PRESIDENT AND CEO

"We redefined our strategy with the goal of highlighting a management style that promotes collaboration with all partners for the future of genomics in Québec."

2008-2009 was a year that Génome Québec proved it plays a pertinent and complex role. A pertinent role for genomics in Québec because we can be proud of our achievements and important contributions to its development. To name a few examples from last year's results, the research funds under our responsibility reached a record high and our four technological centres earned record revenues with an increase of 45% over the previous year.

A complex role as well, because ensuring our progress means adapting to the realities and changes in genomics research. With that in mind, and feedback from our partners, we gave some consideration to our role and how to exercise it. As a result, we redefined our strategy with the goal of highlighting a management style that promotes collaboration with all partners for the future of genomics in Québec. The changes, as you know, led to the restructuring of the management team, including the nomination of a new President and CEO and a new Interim Vice President of Scientific Affairs, Mrs. Catalina Lopez-Correa. Thereafter, an expanded executive committee was put in place, and continues to examine internal and external processes. In this respect, 2008-2009 is considered a transitional year for Génome Québec.

As for 2009-2010, it will be a year to fall back on our fundamental skills, that is, to support the Québec scientific community, and with it, build and energize an innovative bond in genomics. In addition to managing more funds than ever, we will re-establish our programs and diversify our public and private financing sources in order to maintain stable investments for genomics research. To that end, Génome Québec will actively participate in advisory process updates for the Québec Research and Innovation Strategy.

Finally, I would like to sincerely thank our partners who have guided us towards the approach we now have; our loyal employees who share our new vision; Genome Canada, for their invaluable contribution to our activities; and our board of directors, for having confidence in me and granting me the honour of being President and CEO.

Jean-Marc Proulx
President and CEO

SCIENTIFIC ACTIVITY REPORT
Génome Québec



"The achievements of Québec research scientists in 2008-2009 prove that Québec is now a key player in genomics both on a national and international level."

In 2008-2009, Québec's scientific community once again proved itself outstanding on the genomics scene, namely, the exceptional achievement by the Québec research scientists in Applied Genomics Research in Bioproducts or Crops (ABC) Competition of Genome Canada. More than $26 million, representing 28.5% of allocated sums, were granted to projects that are Québec led or co-led.

Congratulations to Professors Adrian Tsang and Vincent Martin of Concordia University and Thomas Bureau of McGill University, whose innovative research allows Québec to be a frontrunner in the bioproducts and crops sector.

Québec research scientists are also well known for their high quality publications in prominent scientific journals such as *Science, Nature Genetics, Nature Medicine, Genome Research, PLoS Genetics and the European Journal of Human Genetics*. These publications are the fruit of dedicated teamwork and global collaboration efforts; they represent the results of outstanding research in life sciences and confirm the leadership role of the Québec scientific community in genomics.

Some examples of publications:

- Publication in *Nature Genetics* – A team of international scientists that includes Rob Sladek, Constantin Polychronakos and Alexandre Montpetit from the McGill University and Génome Québec Innovation Centre, discovers three genes that increase the risk of severe obesity in kids and adults.
- Publication in *Cancer Research* – The team of Professor Sherif Abou Elela from the Génome Québec and Université de Sherbrooke RNomics Centre discovers new breast cancer markers that will allow better evaluation of treatments for this disease.

The accomplishments of the Technological Centres shined here at home as it did overseas. For example, the McGill University and Génome Québec Innovation Centre is considered to be a pioneer in many regards. The Centre is the only organization in Canada to hold three Illumina CSPro certifications, the first in Canada to provide ultra-high throughput GS-FLX sequencing and the first in the world to be named Sequenom Genotyping Centre of Excellence. As for the Génome Québec and Montreal Heart Institute Pharmacogenomics Centre, projects are underway with high profile national and multinational clients, such as Pfizer, AstraZeneca, VIA Pharmaceuticals and Canadian Blood Services. Finally, with the launching of the Génome Québec and Centre hospitalier affilié universitaire régional de Chicoutimi Biobank, Québec becomes the only place in North America with an infrastructure that offers automated DNA storage services at room temperature.

GÉNOME QUÉBEC TODAY AND TOMORROW

These achievements prove that Québec is now a key player in genomics both on a national and international level. Génome Québec is proud to contribute to such an accomplishment and wishes to continue supporting the scientific community on its journey to success. In light of recent changes in perspective within the organization and taking the current issues in genomics into account, we feel it is important for us to specify our approach in the years to come in order to reach our objective. It is our pleasure to present to you our thoughts and goals in this area.

Globally speaking, genomics is becoming more and more complex and technology is evolving rapidly. Developing strategic sectors in Québec proves to be more pertinent than ever. Therefore, it is important to target research areas, and also to discover unique technological applications for those niche fields where we specialize. In both cases, we intend to focus our priorities on science and scientists and try to identify the most productive research field where we will focus our efforts and proceed in close collaboration with research scientists, universities and our other partners.

To make up for the possibility of unstable investments in genomics, we will take action to diversify our financial sources by trying to establish partnerships with national and international organizations. Also, considering the extent of resources to bring genomics projects to successful conclusions, we count on interprovincial and international collaboration. Essentially, we must expand our horizons on financial as well as research planning.

In conclusion, if the vision and mission stated in the 2008-2011 business plan remain unchanged, new strategic approaches have been defined and we will continue to evolve. Joining forces with the scientific community to move forward must now be our priority. Transparency, collaboration and the support of research scientists will always be on our mind, in addition to a financial and scientific control system that is better suited for dynamic and innovative research.



Catalina Lopez-Correa
Interim Vice President, Scientific Affairs

PUBLIC AFFAIRS AND COMMUNICATIONS

"The Public Affairs and Communications Department's activities reflect its approach in promoting genomics in Québec."

To promote genomics and Québec scientists – this was the goal of the Public Affairs and Communications Department in 2008-2009.

In this regard, two promotional campaigns were held in November and December 2008. The accomplishments of Québec scientists were highlighted through ads broadcasted on *RDI* and featured in magazines.

Likewise, "The Geee! In Genome" exhibition, presented in Thetford Mines, aimed to create public awareness of genomics. With over 2,000 visitors, the exhibition provided an opportunity to promote science to young people in particular, a key element to stimulate a new generation of scientists for Québec.

Another of our initiatives, supporting the same idea, is the creation of *Génomia*, an interactive video game that targets youth ages 13-17. *Génomia* is a novel educational tool that allows young people to learn more about genomics in a virtual and fun-filled universe. It will be online with free access in June 2009. With the intention to convey genomics knowledge, two symposiums were organized to target the scientific community. The first one, *Pharmacogenomics Now: Minimize Risks and Maximize Benefits*, was developed in partnership with Cambridge Healthtech Institute. The second one, *Genetic Testing: The Power of Knowledge*, focused on the ethical, economic, environmental, legal and social issues of genomics.

Strengthened by these achievements, the Public Affairs and Communications Department is excited about the new challenges that await them in 2009-2010. More specifically, we will work closely with the Scientific Affairs Department in order to consolidate Génome Québec's relationship with its partners and lay out a new management philosophy.

Marie-Kym Brisson
Director, Public Affairs and Communications

GÉNOME QUÉBEC TECHNOLOGICAL CENTRES

1 - McGill University and Génome Québec Innovation Centre
2 - Génome Québec and Montreal Heart Institute Pharmacogenomics Centre
3 - Génome Québec and Université de Sherbrooke RNomics Centre
4 - Génome Québec and Centre hospitalier affilié universitaire régional de Chicoutimi Biobank

The clientele from the academic and private sectors is growing and expanding, especially among the scientific communities outside of Québec.

Year after year, the Génome Québec Technological Centres and their partners continue to perfect their processes in strategic application areas and witness their unique expertise becoming more and more renowned. As a result, their clientele from the academic and private sectors is growing and expanding, especially among the scientific communities outside Québec. This noticeable trend in 2008-2009 provides proof of their excellent services, made possible by a group of highly qualified professionals who work there.

The recent launching of the Génome Québec and Centre hospitalier affilié universitaire régional de Chicoutimi Biobank brings the total number of technological centres to four. Thus, Québec's reputable expertise in genotyping, functional genomics, proteomics, sequencing, RNomics and pharmacogenomics is completed by an innovative specialty: biological and non-biological sample storage. For Génome Québec, there is no doubt that this new infrastructure will help reinforce the competitive nature of Québec's innovative genomics system.

GÉNOME QUÉBEC TECHNOLOGICAL CENTRES

1

THE MCGILL UNIVERSITY AND GÉNOME QUÉBEC INNOVATION CENTRE

"With its initiatives combined with a firm commitment to quality services and client satisfaction approaches, the Innovation Centre's clientele continues to increase."

After seven years of progress and development, more than ever, the McGill University and Génome Québec Innovation Centre is in a position to offer genomics research scientists technologies and unique expertise to achieve their projects. In this regard, we celebrated the accomplishment of becoming the first Center of Excellence in the world certified by Sequenom for genotyping technology. It is a noteworthy honour in addition to the three Illumina CSPro certifications received in the past few years.

With the desire to maintain its cutting-edge technologies in order to meet the growing needs of the scientific community, the Innovation Centre continuously upgrades its equipment and updates its processes. For example, a new Illumina GA-II ultra-high throughput sequencer and other high-tech equipment for epigenetics research were installed last year. Furthermore, thanks to an exceptional team, the proteomics platform was reorganized; new methods were developed for preparing complex biological samples and restructuring the bioinformatics pipeline.

With its initiatives combined with a firm commitment to quality services and client satisfaction approaches, the Innovation Centre's clientele continues to increase. To be exact, 647 academic and industrial research scientists called upon our expertise last year, compared to 580 from the previous fiscal year, a 12% increase. Finally, it is worth mentioning that the Innovation Centre embarked on publicizing its expertise to the scientific community by organizing Génome Québec *Rendez-Vous* sessions. The first ones were held in April 2008 and February 2009 and focused on proteomics, ultra-high throughput sequencing techniques and the FlexArray software. The pertinence of such meetings was confirmed by the number of participants: nearly 25 distinguished lecturers and more than 375 research scientists were in attendance.

A FEW WORDS ON 2009 - 2010

One of our priorities is to begin the technological support of eight large-scale projects recently funded by Genome Canada within the ABC Competition, three of which were co-funded by Génome Québec. Most of these projects, related to the environment and agriculture, will be requiring ultra-high throughput sequencing and proteomics technologies. For this reason, we must continue developing new protocols and tools for bioinformatics analysis that are more robust and efficient.

Daniel Tessier
Senior Director
Operations and Business Development

2

THE GÉNOME QUÉBEC AND MONTREAL HEART INSTITUTE PHARMACOGENOMICS CENTRE

"The Pharmacogenomics Centre is ready to further expand its range of services, develop its clientele and optimize its processes, while delivering the same top-level quality."

In 2008-2009, the high point for the Génome Québec and Montreal Heart Institute Pharmacogenomics Centre was unquestionably its relocation to the Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre. Now established in ultra-modern laboratories equipped with new cutting-edge technology, such as Solexa, Illumina, Sequenom and Affymetrix, the Pharmacogenomics Centre is ready to further expand its range of services, develop its clientele and optimize its processes, while delivering the same top-level quality, always in keeping with Good Laboratory Practices (GLP). Emboldened by these improvements, the Centre was able to accelerate the production of genetic tests, leading to the successful launch of projects for high-profile clients, such as Pfizer, AstraZeneca, VIA Pharmaceuticals and Canadian Blood Services. Other key initiatives, such as the genotyping of the Héma-Québec donor base, also moved ahead this year.

In spite of efforts related to the move, the Pharmacogenomics Centre more than tripled last year's revenue, reaching record profits. This stellar 700-percent increase was due mainly to an upsurge of activities for commercial clients and to two large-scale projects, the "Pharmacogenomics of drug efficacy and drug toxicity in the treatment of cardiovascular disease" and the "Québec Cardiovascular Pharmacogenomics Research Initiative."

A FEW WORDS ON 2009 - 2010

In the coming year, the Pharmacogenomics Centre expects to launch new ultra-throughput sequencing services and develop its quality systems, genetic panels and bioinformatics tools. These changes will ensure the success of the two large-scale projects mentioned above, the first involving the screening of 7,000 patients through custom genetic panels that target cardiovascular diseases, hypertension and ADME/toxicity collectively analyzed on a genomics scale. As for the second initiative, it will focus on technology transfer of proprietary tests and the implementation of an electronic guidance system that will foster better knowledge transfer from the Pharmacogenomics Centre to the clinical setting.

Andrea Smith
Director, Business Development

THE GÉNOME QUÉBEC AND UNIVERSITÉ DE SHERBROOKE RNOMICS CENTRE

"The Génome Québec and Université de Sherbrooke RNomics Centre provides academic and industrial research scientists expertise and the most unique technologies in the world for rapid acquisition and analysis of RNA molecular genetics data."

The Génome Québec and Université de Sherbrooke RNomics Centre provides academic and industrial research scientists expertise and the most unique technologies in the world for rapid acquisition and analysis of RNA molecular genetics data. To be exact, its exclusive resources enable the identification of RNA biomarkers and therapeutic targets for complex diseases such as cancer. Eventually these biomarkers can help in the development of new tools for prevention, diagnosis and treatment. Thus, in order to remain in the forefront of genomics research, the RNomics Centre must continuously move ahead in the development and implementation of revolutionary applications and methods.

THE CENTRE FOCUSED ITS ENERGY IN 2008-2009 WITH THAT IN MIND; HERE ARE THE HIGHLIGHTS:

- Automation of cell transfection and its validation by PCR.
- Establishment of an amplification method for RNA in low concentration.
- Primer designing, data management and result analysis of multiplex PCR method.
- Molecular quantification of telomeres.
- Quality control of quantitative PCR.
- Multidisciplinary coaching of projects.
- Completion of a work agreement complementary to the McGill University and Génome Québec Innovation Centre for PCR quantitative services.
- Implementation of financial management tools integrating other Génome Québec technological centres.

Moreover, the RNomics Centre once again proved its outstanding capacity to perform breakthrough science. Under the direction of Professor Sherif Abou Elela, Scientific Director of the RNomics Centre, a team of research scientists detected new molecular markers associated with the spread of breast cancer. This discovery may lead to a more efficient screening method for the disease. The result of this significant research was published in the journal *Cancer Research* (2008 Nov 15; 68(22): 9525-31). The RNomics Centre conducted this research within a large-scale project on many genes of which certain variants could be associated with the transformation of healthy tissue into cancerous tissue. The project will be further developed in the next few years.

UPCOMING PROJECTS IN 2009 - 2010

Now that its technological and scientific foundation is solidly established, the RNomics Centre intends to continue to advance beyond this important project by collaborating with qualified and highly talented scientists.

Daniel Tessier
Senior Director
Operations and Business Development

4

GÉNOME QUÉBEC AND CENTRE HOSPITALIER AFFILIÉ UNIVERSITAIRE RÉGIONAL DE CHICOUTIMI BIOBANK

"The Biobank becomes the first of its kind in North America to offer a complete automated DNA storage service at room temperature."

In 2008-2009, the fourth Génome Québec Technological Centre was born: the Génome Québec and Centre hospitalier affilié universitaire régional de Chicoutimi Biobank. This achievement is the result of close collaboration between the two partners after which the Biobank is named. The Centre is now ready to take on full activities, becoming the first of its kind in North America to offer a complete automated DNA storage service at room temperature. It is also recognized internationally for its other technological platforms that complete its storage service portfolio for biological and non-biological samples. Furthermore, the combined infrastructures of the Biobank, both efficient and ultramodern, guarantee the highest quality, integrity and security standards.

2008 - 2009 HIGHLIGHTS

- The completion of an important restructuring project transformed the former Augustinian Monastery gymnasium into a biobank of cutting-edge technology. All necessary equipment for the operations is now installed and functional.
- Thanks to the ingenuity of the team, the harmonization of multiple technologies operating the Biobank was successfully accomplished. Similarly, a number of integrated tools and innovative protocols were developed, improving productivity while maintaining the quality, integrity and security standards we value.
- The Biobank and the CARTaGENE team continued to work in partnership for the implementation of this important community project.

UPCOMING PROJECTS IN 2009 - 2010

- Project CARTaGENE will start its main phase of sample collecting shortly, thus becoming the first and most important client of the Biobank. Every month, samples from thousands of individuals will be entrusted to the Biobank for storage.
- Creation of an ethics and governance committee for the Biobank.
- Establishing a *Quality* system and obtaining an ISO certification.
- Developing business opportunities, acquiring new clients and partners.

Steve Arsenault
Director

HUMAN RESOURCES
Génome Québec

"The exceptional achievements of 2008-2009 are the result of our employees' total commitment to the rapid development of genomics."

Thanks to our highly qualified employees, in 2008-2009 the four Génome Québec Technological Centres provided innovative services to 695 academic and industrial research scientists, thus contributing to the advance of important scientific developments.

The contribution and expertise of our employees enabled Génome Québec to receive two important certifications (from Sequenom and Illumina); to create a Centre of Excellence in personalized medicine; to proceed with the development of complex technologies and to multiply service agreements in Québec and Canada. The exceptional achievements of 2008-2009 are the result of our employees' total commitment to the rapid development of genomics. Moreover, a 5% decrease in the annual turnover rate reflects the interest of our employees in pursuing a career with us and consequently, our commitment to invest in developing their skills.

The Génome Québec team is ready to support the scientific community by its desire to push the limits of genomics. In order to continue on the path of excellence in 2009-2010, Génome Québec encourages its employees to set ambitious and realistic objectives that are aligned with international standards. In turn, Génome Québec will actively recognize each accomplishment.

Pierre Francoeur
Director, Human Resources



PROFESSIONAL CERTIFICATIONS OF GÉNOME QUÉBEC EMPLOYEES

TECHNOLOGICAL CENTRES EMPLOYEES' ACHIEVEMENTS

- Daniel Vincent (genotyping)
  "We developed new applications for CNV and DNA-methylation analyses."

- Hao Fan Yam (sequencing)
  "We implemented a new sequencing technology (MPS) and BaseXpress, a 24-hour service."

- Steve Arsenault (Biobank)
  "We set up the only automated biobank at room temperature in North America."

- Line Roy (proteomics)
  "We determined our niche market by initiating the integration of proteomics to genomics."

- Louis Létourneau (bioinformatics)
  "From a billion genotypes to protein annotations, bioinformatics has many great challenges."

- Isabelle Guillet (functional genomics)
  "Microarray hybridization processes were performed on 2,644 samples this year – the best output in our history."

- Philippe Thibault (RNomics)
  "We have developed an automated method of cell transfection and its validation by PCR."

- Yannick Renaud (pharmacogenomics)
  "The team regrouped and developed technological innovations for the rapid development of personalized medicine."

"In order for Génome Québec to provide superior services to its partners, clients as well as the scientific community as a whole, the department is taking steps to focus on optimizing internal efficiency."

The Finance Department made great efforts in 2008-2009 to complete previously initiated strategies in risk management, information technology and standardization of the processes common to all Technological Centres.

After assessing the inherent key risks in Génome Québec's operations, regulations were put in place in order to reduce their impact. We can now confirm that Génome Québec is working with an efficient risk management plan helping us achieve our objectives.

Following the successful implementation of the integrated information system, we further computerized processes for quotation, invoicing, purchasing and report generating, as well as reorganizing and digitizing all contracts and documents. By centralizing information and computerizing the tasks that are generated, we now have better data control and higher productivity.

We also standardized the costs of all services offered by the Technological Centres and adjusted sales prices accordingly. Consequently, the Centres now have the capacity to establish their service fees.

Thanks to these improvements, we are now ready to face the upcoming challenges in 2009-2010. More specifically, the department will focus on the following priorities:

- Work openly and inclusively with our established partners when prospecting new clients, developing technological platforms and maintaining competitive prices for our services in order to assure sustainability of the technological centres.
- Finalize ongoing agreements and prepare the ones with McGill and Concordia Universities resulting from the ABC competition.
- Document and improve the governance process of Génome Québec.
- Adopt a proactive approach by involving employees in financial data analysis of upcoming projects upstream, enabling managers to make informed decisions.

The actions to come, like those from last year, focus on optimizing internal efficiency for Génome Québec in order to provide superior services to its partners and clients as well as the scientific community as a whole.

Raymond Castonguay
Vice President, Finance and Investments

FINANCIAL STATEMENTS
Génome Québec

FINANCIAL ACTIVITIES AS AT MARCH 31, 2009

As at March 31, 2009, our portfolio included fourteen genomics and proteomics projects, for a total budget of $140 million. During the 2008-2009 fiscal year, Génome Québec invested $43.1 million. This sum, combined with the $14.8 million investment by other partners, brings our overall portfolio to $57.9 million.

Genome Canada and the Ministère du Développement économique, de l'Innovation et de l'Exportation du Québec are Génome Québec's main funding agencies.

The business volume generated by large-scale projects has increased this past year, amounting to $39.5 million, despite the end of the Health Competitions. In addition, the PRIVAC Competition experienced stellar growth in its activities, for a total of $12.4 million. The fiscal year also saw the launch of the Technological Development Competition.

For the year ending March 31, 2009, sales from our four Technological Centres grew to $15.9 million, a 45% increase from the previous year. This growth is mostly due to a rise in activities among academic clients, for a total of $2.8 million – or 66% – and among external clients for $1.9 million – or a five-fold increase compared to the previous financial period. The Technological Centres presented an excess of revenue over expenses amounting to $1.2 million in restricted net assets and $176,994 in non-restricted assets.

The general and administrative fees, which were adjusted for some of the Centres' expenses and for other one-time expenses, totalled $3.9 million during the fiscal year, representing 6.7% of total investments, compared to $3.4 million – or 6.6% – last year. Salary increases and a greater focus on scientific activities, consultations and information of the general public are behind this rise. Investment revenue reached $826,429 for a performance of nearly 3.5%.

During the fiscal year, the excess of revenue over expenses totalled $1.4 million. Of this surplus, non-designated net assets rose by $449,585, for a sum of $724,671. These net assets represent a possible source of funding for future activities in keeping with the Organization's strategic development plans.

Finally, Génome Québec has respected the terms and conditions in compliance with the contractual agreements it has signed with its major financial partners.

Jean-Marc Proulx
President and CEO
Génome Québec

Raymond Castonguay
Vice President, Finance and Investments
Génome Québec

GÉNOME QUÉBEC AND PARTNERS - 2008-2009



GÉNOME QUÉBEC AND ACTIVITIES TOTAL INVESTIMENT OF $57.9 M



AUDITORS' REPORT TO THE DIRECTORS

We have audited the statement of financial position of Génome Québec as at March 31, 2009 and the statements of operations, changes in net assets and cash flows for the year then ended. These financial statements are the responsibility of the Corporation's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Those standards require that we plan and perform an audit to obtain reasonable assurance whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation.

In our opinion, these financial statements present fairly, in all material respects, the financial position of the Corporation as at March 31, 2009 and the results of its operations and its cash flows for the year then ended in accordance with Canadian generally accepted accounting principles.

KPMG LLP*

Chartered Accountants
Montréal, Canada
May 28, 2009

*CA Auditor permit no 14553

STATEMENT OF FINANCIAL POSITION

March 31, 2009, with comparative figures for 2008

	2009	2008
Assets		
Current assets:		
Cash and cash equivalents	$ 2,572,420	$ 4,296,990
Short-term investments	6,311,973	18,372,786
Accounts receivable and work in progress	2,257,458	2,214,624
Contribution receivable (note 3)	2,065,872	–
Advances to genomic research projects	687,345	1,139,745
Inventories	1,164,428	723,499
Prepaid expenses	796,932	424,409
	15,856,428	27,172,053
Long-term investments (note 4)	14,947,232	–
Capital assets (note 5)	4,186,646	4,990,947
	$ 34,990,306	$ 32,163,000
Liabilities and Net Assets		
Current liabilities:		
Accounts payable and accrued liabilities	$ 3,508,014	$ 3,635,867
Deferred revenues	195,741	1,661,097
Contributions to be reimbursed (note 6 (i))	1,348,170	2,406,246
	5,051,925	7,703,210
Deferred contributions:		
Future expenses (note 6)	23,875,203	19,021,085
Capital assets (note 7)	3,792,392	4,600,912
	27,667,595	23,621,997
Net assets:		
Unrestricted	724,671	275,086
Restricted - Invested in capital assets (note 5)	394,254	390,035
Restricted - Technology investment fund	1,151,861	172,672
	2,270,786	837,793
Commitments (note 10)		
	$ 34,990,906	$ 32,163,000

See accompanying notes to financial statements.

On behalf of the Board:

, Director

, Director

STATEMENT OF OPERATIONS
Year ended March 31, 2009, with comparative figures for 2008

	2009	2008
Revenues:		
Amortization of deferred contributions related to expenses (note 6)	$ 32,761,660	$ 34,708,438
Amortization of deferred contributions related to capital assets (note 7)	2,433,359	1,692,870
Investment income	826,429	1,049,899
Revenues from technology centers	15,915,953	10,950,907
Revenues from intellectual property	–	15,000
	51,937,401	48,417,114
Expenses:		
Genomic research projects	24,646,814	28,453,865
Technology centers operational cost	18,347,570	13,911,145
Technology investment fund	89,427	–
General and administrative	4,566,285	3,834,296
Strategic initiatives	302,036	–
Depreciation of capital assets	2,433,359	1,692,870
Depreciation of restricted capital assets	118,917	68,830
	50,504,408	47,961,006
Excess of revenues over expenses	$ 1,432,993	$ 456,108

See accompanying notes to financial statements.

STATEMENT OF CHANGES IN NET ASSETS

Year ended March 31, 2009, with comparative figures for 2008

				2009
	Restricted		Unrestricted	Total
	Invested in capital assets	Technology investment fund		
Net assets, beginning of year	$ 390,035	$ 172,672	$ 275,086	$ 837,793
Excess of revenues over expenses	(118,917)	1,191,752	360,158	1,432,993
Invested in capital assets	123,136	(212,563)	89,427	–
Net assets, end of year	$ 394,254	$ 1,151,861	$ 724,671	$ 2,270,786

				2008
	Restricted		Unrestricted	Total
	Invested in capital assets	Technology investment fund		
Net assets, beginning of year	$ –	$ 153,524	$ 228,161	$ 381,685
Excess of revenues over expenses	(68,830)	19,148	505,790	456,108
Invested in capital assets	458,865	–	(458,865)	–
Net assets, end of year	$ 390,035	$ 172,672	$ 275,086	$ 837,793

See accompanying notes to financial statements.

STATEMENT OF CASH FLOWS

Year ended March 31, 2009, with comparative figures for 2008

	2009	2008
Cash flows from operating activities:		
Excess of revenues over expenses	$ 1,432,993	$ 456,108
Adjustments for:		
Depreciation of capital assets	2,552,276	1,761,700
Amortization of deferred contributions related to expenses (note 6)	(32,761,660)	(34,708,438)
Amortization of deferred contributions related to capital assets (note 7)	(2,433,359)	(1,692,870)
	(31,209,750)	(34,183,500)
Contributions received	39,240,617	46,149,209
Changes in assets and liabilities:		
Accounts receivable and work in progress	(42,834)	(311,825)
Contribution receivable	(2,065,872)	–
Advances to genomic research projects	452,400	(1,260,241)
Inventories	(440,929)	(338,677)
Prepaid expenses	(372,523)	(69,844)
Accounts payable and accrued liabilities	(127,853)	186,327
Deferred revenues	(1,465,356)	1,587,520
Contributions to be reimbursed	(1,058,076)	(698,658)
	(5,121,043)	(905,398)
	2,909,824	11,060,311
Cash flows from investing activities:		
Change in short-term investments	12,060,813	(11,449,656)
Net increase in long-term investments	(14,947,232)	–
Purchase of capital assets	(1,747,975)	(3,099,433)
	(4,634,394)	(14,549,089)
Net decrease in cash and cash equivalents	(1,724,570)	(3,488,778)
Cash and cash equivalents, beginning of year	4,296,990	7,785,768
Cash and cash equivalents, end of year	$ 2,572,420	$ 4,296,990

Additional information (note 8)
See accompanying notes to financial statements.

NOTES TO FINANCIAL STATEMENTS

Year ended March 31, 2009

Génome Québec (the "Corporation") was incorporated on June 29, 2000 under Section II of the Canada Corporations Act. Génome Québec is a not-for-profit organization and has the following objectives:

a) to develop and maintain in the province of Quebec a coordinated approach and an integrated strategy in the fields of genomic research (including health, agriculture, environment, forestry and fisheries) by bringing together the intervening parties from the industry, governments, universities, research centers and laboratories, as well as any other person and organization interested in advancing the goals of the Corporation;

b) to create, operate and support an infrastructure network in genomics giving Quebec researchers access to a high technology expertise;

c) to ensure that researchers have access to the necessary equipment and installations to undertake research and development projects in genomics, and to allow for the training of researchers and technologists;

d) to raise the awareness of the population to the necessity of research in genomics, to the usefulness and consequences of the outcome from this research, to ensure an ethical environment for the researchers and to contribute to public awareness regarding the stakes involved in genomic research.

1. Significant accounting policies:

a) Cash and cash equivalents:

Cash and cash equivalents consist of cash as well as all highly liquid short-term investments which have a maturity of less than three months from the date of acquisition.

b) Investments:

Short-term investments and long-term investments, redeemable at any time, are recorded at the market value.

c) Work in progress:

Work in progress is recorded at the pro rata billing value of the work completed.

d) Inventories:

Inventories are represented by supplies which will be utilized by the technology centers. The supplies are recorded at the lower of cost and net realizable value. The cost is determined using the first in, first out method.

e) Advances and charges related to genomic research projects:

The advances represent the excess of the contributions to the research projects, including work performed by the technology centers, over the claims received which are recognized in the statement of operations.

f) Revenue recognition:

The Corporation follows the deferral method of accounting for contributions which include mainly funding from Genome Canada and the ministère du Développement économique, de l'Innovation et de l'Exportation du Québec. Unrestricted contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

Externally restricted contributions are recognized as revenue in the year in which the related expenses are incurred. Restricted contributions related to the purchase of capital assets are deferred and amortized to revenues using the same methods and rates of the related capital assets.

Revenues from technology centers are sequencing, genotyping, biochip, biological sample storage and proteomics services. Revenues are recognized on the basis of the services rendered.

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

Year ended March 31, 2009

1. Significant accounting policies (continued):

g) Capital assets:

Capital assets are stated at cost. Depreciation is provided for using the following methods, period and annual rates:

Asset	Method	Period/rate
Leasehold improvements	Straight-line	Remaining lease term
Furniture and fixtures	Declining balance	20 %
Equipment	Declining balance and straight-line	30% and term of project
Computers and software	Declining balance	30 %

h) Financial instruments:

All financial instruments are classified into one of the following five categories: held-for-trading, held-to-maturity investments, loans and receivables, available-for-sale financial assets or other financial liabilities. All financial instruments are included on the balance sheet and are measured at fair market value, with the exception of loans and receivables, investments held-for-maturity and other financial liabilities, which will be measured at amortized cost. Subsequent measurement and recognition of changes in fair value of financial instruments depend on their initial classification.

Held-for-trading financial investments are measured at fair value, and all the gains and losses are included in net income in the period in which they arise. Available-for-sale financial instruments are measured at fair value with revaluation gains and losses included in other comprehensive income until the asset is removed from the balance sheet. The Corporation has classified its short-term and long-term investments as "held-for-trading" and they are accounted for at fair value. The Corporation has classified its accounts receivable and work in progress, contribution receivable and advances to genomic research projects as loans and receivables and its accounts payable and accrued liabilities as other financial liabilities which are measured at amortized cost.

i) Use of estimates:

The preparation of financial statements in conformity with generally accepted accounting principles requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Significant areas requiring the use of management's estimates relate to the determination of the useful life and the estimated residual value of the capital assets along with the recoverability of long-term investments. Accordingly, actual results could differ from those estimates.

2. Restricted net assets:

Under agreements, the excess of revenues over expenses generated by these technology centers includes restrictions for its reinvestment:

For the pharmacogenomics center, for the first three years ending March 31, 2009, the first $1,000,000 of excess must be reinvested in the center to insure its development. As at March 31, 2009, the excess is $774,246.

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

Year ended March 31, 2009

2. Restricted net assets (continued):

For the RNomics center, the first $200,000 of excess which represents the start-up costs must reimburse Génome Québec's contribution. As at March 31, 2009, the start-up costs total $409,634.

For the Innovation center, a technology investment fund has been established to implement new technologies and pay for other expenses incurred by the center. The contributions represent a percentage of the revenues generated from services rendered to Genomics research projects and Canadian academics. As at March 31, 2009, six projects have been approved and the net assets realized during the year, net of the affectations, total $377,615.

3. Contribution receivable:

As at April 13, 2009, the Corporation has received a contribution of $2,700,000 from the Government of Québec following a decree adopted on December 18, 2008 to finance operational expenses and projects start-up costs. As at March 31, 2009, the contribution receivable represents the expenses incurred during the year.

4. Long-term investments:

	2009	2008
Bonds, provincials and municipals, with a yield at cost, considering that the bond is held to maturity, between 1.52% and 3.60%, and a maturity ranging from April 2010 to April 2011	$ 14,947,232	$ –

5. Capital assets:

			2009	2008
	Cost	Accumulated depreciation	Net book value	Net book value
Leasehold improvements	$ 25,971	$ 25,971	$ –	$ –
Furniture and fixtures	251,126	168,266	82,860	104,699
Equipment - technology centers	5,297,501	3,817,100	1,480,401	1,900,117
Equipment - restricted assets - technology centers	582,001	187,747	394,254	390,035
Equipment - research projects	11,534,867	9,618,226	1,916,641	2,193,343
Computer and software	574,836	262,346	312,490	402,753
	$ 18,266,302	$ 14,079,656	$ 4,186,646	$ 4,990,947

6. Deferred contributions related to future expenses:

The Corporation receives contributions from Genome Canada and the ministère du Développement économique, de l'Innovation et de l'Exportation du Québec. These contributions will be administered and distributed in accordance with the terms and conditions of the related agreements.

Deferred contributions related to expenses of future periods represent the unspent externally restricted funding and related investment income for the purposes of providing contributions to eligible recipients and paying operating and capital expenditures in future periods.

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

Year ended March 31, 2009

6. Deferred contributions related to future expenses (continued):

The deferred contributions are :

	Balance March 31, 2007	2008 Transactions	March 31, 2008	2009 Transactions	Balance March 31, 2009
Contributions:					
Genome Canada	$ 115,831,044	$ 22,929,257	$ 138,760,301	$ 16,919,810	$ 155,680,111
Government of Québec	99,582,617	22,900,000	122,482,617	20,727,871	143,210,488
Canada Economic Development	–	431,829	431,829	1,114,260	1,546,089
VRQ	3,760,560	–	3,760,560	–	3,760,560
Cancer Care Ontario	3,113,815	–	3,113,815	478,398	3,592,213
Genome Prairies	1,947,093	–	1,947,093	–	1,947,093
FQRNT	500,000	–	500,000	–	500,000
FRSQ	439,000	–	439,000	–	439,000
MSSS	100,000	–	100,000	–	100,000
Other	73,805	(1,954)	71,851	–	71,851
Natural resources	100,000	–	100,000	–	100,000
HUPO	11,509	(11,509)	–	–	–
	225,459,443	46,247,623	271,707,066	39,240,339	310,947,405
Investment income	2,871,270	–	2,871,270	–	2,871,270
Reclassification of completed projects [(i)]	(1,558 ,296)	(1,546,608)	(3,104,904)	278	(3,104,626)
Recovery of taxes on goods and services [(ii)]	1,008,876	(103,319)	905,557	–	905,557
Amount amortized to revenues	(200,070,196)	(34,708,438)	(234,778,634)	(32,761,660)	(267,540,294)
Amount invested in capital assets	(15,938,702)	(2,640,568)	(18,579,270)	(1,624,839)	(20,204,109)
	$ 11,772,395	$ 7,248,690	$ 19,021,085	$ 4,854,118	$ 23,875,203

i) The financial support of many research projects and current and capital expenses related to Competitions I, II and the Applied Genomics and Proteomics Research in Human Health ended on March 31, 2009. Contributions received in excess of the related accumulated expenses are reclassified as contributions to be reimbursed.

ii) The Corporation received an opinion from the tax authorities allowing the recovery of the full amount of the goods and services input tax credit. Previously, the reimbursement was limited to a reduced rate. The recovered taxes are presented as deferred contributions until their allocation by management.

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

Year ended March 31, 2009

7. Deferred contributions related to capital assets:

Deferred contributions related to capital assets represent the unamortized amount of contributions received for the purchase of capital assets. The amortization of such contributions is recorded as revenue in the statement of operations. The changes in balances of the deferred contributions are as follows:

	2009	2008
Opening balance	$ 4,600,912	$ 3,653,214
Add allocation of funding for capital asset purchases	1,624,839	2,640,568
Less amount amortized to revenues	(2,433,359)	(1,692,870)
Ending balance	$ 3,792,392	$ 4,600,912

8. Supplemental cash flow information:

	2009	2008
Non-cash transactions excluded from the change in deferred contributions:		
Interest receivable	$ –	$ (4,905)
Amount transferred to deferred contributions related to capital assets	(1,624,839)	(2,640,568)
Amount reclassified as contributions to be reimbursed	278	(1,546,608)
	$ (1,624,561)	$(4,192,081)

9. Financial instruments:

Fair value, credit risk and interest rate:

The Corporation determined that the book value of its short-term financial assets and liabilities, including cash and cash equivalents, short-term investments, accounts receivable and accounts payable and accrued liabilities, approximated their fair value due to the short-term nature of these instruments.

The credit risk arises from the possibility of financial loss caused by the inability of a party to fulfill its contractual obligation. The Corporation performs ongoing monitoring of its risk exposure and takes appropriate actions to reduce the probability that such risk leads to losses.

NOTES TO FINANCIAL STATEMENTS (CONTINUED)

Year ended March 31, 2009

9. Financial instruments (continued):

Fair value, credit risk and interest rate (continued):

Financial instruments that could expose the Corporation to important credit risk mainly consist of short-term bonds. The Corporation's investment policy has been established to secure and protect capital so that current and future cash flow requirements can be met.

Short-term bond investments consist primarily of fixed income securities issued by governmental and municipal organizations granted high credit rating. The weighted average yield at cost, considering that the bound is held to maturity, is 2.76%.

10. Commitments:

In accordance with agreements entered into by Genome Canada with regard to a financial support commitment of $73,720,573 related to the Applied Genomics and Proteomics Research in Human Health, to Competition III, to the International Consortium Initiatives ("ICI") and to New Technology Development ("Tecdev"), the Corporation has agreed, among other things, to obtain equivalent financing commitments from other parties. In this matter, financial commitments from the Government of Québec amounted to $49,601,708 and an amount of $23,041,940 is committed from other parties, of which $2,962,525 remains to be finalized.

In accordance with an agreement entered into by the Government of Québec regarding a financial support of $18,000,000 related to the Privac Competition, to strategic intiatives and to administrative center costs, the Corporation has agreed, among other things, to obtain financing commitments from other parties in the amount of $20,435,768, of which $425,292 remains to be finalized.

The Corporation's research projects portfolio totals $112,469,959. As at March 31, 2009, the residual balance for these projects totals $50,546,957.

The Corporation entered into various agreements for services and rents. These agreements expire at various dates until 2013. The payments under these agreements for the next years are: $641,035 in 2010, $506,761 in 2011, $272,400 in 2012 and $66,575 in 2013.

11. Comparative figures:

Certain comparative figures for 2008 have been reclassified in order to conform with the financial statement presentation adopted in 2009.

MEMBERS OF THE BOARD OF DIRECTORS, COMMITTEES AND EMPLOYEES
Génome Québec

BOARD OF DIRECTORS

- **Jean-Claude Cadieux**, PhD
  Management Consultant, Chairman of the Board
- **Daniel Bouthillier**, PhD
  Executive Director
  Global Site Services, Merck Frosst
- **M^e Jean Brunet**, Stein Monast S.E.N.C.R.L.
  Lawyer, Secretary of the Board
- **Hélène Desmarais**
  Chairman of the Board and Chief Executive Officer
  Centre d'entreprises et d'innovation de Montréal (CEIM)
- **Jean-Paul Gagné,** Publisher Emeritus
  Journal *Les Affaires*
- **Martin Godbout**, PhD
  President and CEO, Genome Canada
- **Gérald A. Lacoste**, Q.C.
  Corporate Director
- **Pierre Prémont**, PhD
  President and CEO
  Fond québécois de la recherche sur la nature et les technologies (FQRNT)
- **Jean-Marc Proulx**
  President and CEO, Génome Québec
- **D^r Jacques Remacle,** Principal Scientific Officer
  Genomics and Systemic Biology Unit
  European Commission, Brussels
- **Geneviève Tanguay**, PhD, Observer
  Assistant Deputy Minister for research and innovation
  Ministère du Développement économique, de l'Innovation et de l'Exportation (MDEIE)
- **Luc Tanguay**, MSc, CFA
  Senior Executive Vice President and CFO
  Theratechnologies Inc.

EXECUTIVE COMMITTEE

- **Jean-Claude Cadieux**
  Management Consultant, Chairman of the committee
- **Gérald A. Lacoste**,
  Corporate Director
- **Jean-Marc Proulx**
  Génome Québec
- **Luc Tanguay**, Theratechnologies Inc.
- **M^e Jean Brunet**, Stein Monast S.E.N.C.R.L.
  Secretary of the Committee

AUDIT/INVESTMENT COMMITTEE

- **Luc Tanguay**, MSc, CFA
  Theratechnologies inc., Chairman of the commitee
- **Jean-Paul** Gagné
  Journal *Les Affaires*
- **Gérald A. Lacoste**, Q.C.
  Corporate Director

STRATEGIC AND SCIENTIFIC ADVISORY BOARD (SSAB)

- **Michel Bouvier**, PhD
  Université de Montréal
- **Michel Georges**, PhD
  Université de Liège
- **Marc Lalande**, PhD
  University of Connecticut Health Center
- **John MacKay**, PhD
  Université Laval
- **Michael Phillips**, PhD
  Génome Québec and Université de Montréal
- **Pierre Tambourin**, PhD
  Génopole Évry
- **Pierre Prémont**, PhD, FQRNT

GE^{3}LS ADVISORY COMMITTEE

- **Bryn William-Jones**, PhD
  Université de Montréal
  Chairman of the committee
- **D^r Renaldo Battista**
  Université de Montréal
- **Alberto Cambrosio**, PhD, McGill University
- **Nancy Gélinas, PhD**
  Université Laval
- **Jean Lachaine, PhD**
  Université de Montréal
- **M^e Nathalie Lecoq**
  Centre hospitalier universitaire Sainte-Justine
- **D^r Suzanne Philips-Nootens**
  Université de Sherbrooke
- **Daniel Sinnett**, Ph D
  Centre hospitalier universitaire Sainte-Justine

PARTNER FORUM

- **D^r Alain Beaudet**, PhD
  Canadian Institutes of Health Research (CIHR)
- **Jacques Beauvais**, PhD
  Université de Sherbrooke
- **Francine Belle-Isle**, PhD
  Université du Québec à Chicoutimi
- **Guy Berthiaume**, PhD
  Université du Québec à Montréal
- **Edwin Bourget**, PhD, Université Laval
- **Luc Castonguay**
  Ministère du Développement économique, de l'Innovation et de l'Exportation du Québec (MDEIE)
- **Louise Dandurand**, PhD, Concordia University
- **Martin Doyon**
  Ministère du Développement économique, de l'Innovation et de l'Exportation du Québec (MDEIE)
- **Joseph Hubert**, PhD, Université de Montréal
- **Denis Thérien**, PhD, McGill University

GÉNOME QUÉBEC EMPLOYEES

Amr Al Mallah
Anne-Marie Alarco
Yolaine Ancellin
Steve Arsenault
Lucian Avram
François Marie Bacot
Guillaume Barreau
Yolande Bastien
Christopher Beck
Alexandre Bélisle
Line Benguerel
Denis Bilodeau
Michal Blazejczyk
Daniel Boismenu
Julie Boudreau
Marc Bouffard
Sara Bourbonnais
Sébastien Brunet
David Bujold
Alice Carey
Emmanuelle Cartier
Raymond Castonguay
Valérie Catudal
Christine Cellier
Fanny Chagnon
Marie-Paule Choquette
Cristina Ciurli
Catherine Côté
Geneviève Dancausse
Marianne Desautels
Marcos Di Falco
Joana Dias
Jacqueline Dionne
Christian Drouin
Anick Dubois
Geneviève Dufour
Mathieu Durand
Nathalie Émond
Isabelle Fillion
Joëlle Fontaine
Pierre Francoeur
Rosalie Fréchette
Julie Gagné
Marie-Josée Gaulin-Marion
Geneviève Geneau
Steve Geoffroy
Claire Goguen
Paul Guelpa
Isabelle Guillet
Nathalie Hamel
Cecilia Hernandez
Abdelmadjid Hihi
Louis Dumond Joseph
Amélie Kirouac
Aisha Kly
André Laberge
Sylvie Laboissière
Marc-André Labonté
Philippe Laflamme
Claude Lamarre
Nancy Lambert
Mathieu Langlois
Sylvie Larouche
Martin Leboeuf
Fabienne Lefebvre
Pierre Lepage
Darie Lessard
Louis Létourneau
Gary Leveque
Catalina Lopez-Correa
Stéphanie Lord-Fontaine
Lizette Mailloux
Yannick Marcon
Sharon Marsh
Aurélie Masurel
Philippe-Antoine Ménard
Jana Mickova
Nancy Milot
Ian Mongrain
Alexandre Montpetit
Corina Nagy
Thuong Ngo
Valérie Normand
Daniel Pépin
Julie Perrone
Truc Pham
Claire Pinsonnault
André Ponton
Jean-Marc Proulx
Yannick Renaud
Yannick Richard
Lyne Robert
Frédérick Robidoux
Sharen Sophie Roland
David Roquis
Line Roy
Lorraine Saule
Laura Sbarra
Donna Sinnett
Andrea Smith
Dennis Spathis
Alfredo Staffa
Daniel Tessier
Marie-Catherine Tessier
Philippe Thibault
Louise Thibault
Thodoros Topaloglou
Julie Vallée
Diane Valois
Tu Linh Van
Tibor Van Rooij
Sylvain Versailles
Yan Vigneault
Daniel Vincent
Hao Fan Yam
Chung-Yan Yuen
Nathalie Zapata
Corine Zotti

RETOMBÉES DES GRANDS PROJETS / LARGE SCALE PROJECT OUTCOMES
Mars / March 2009

	NOMBRE DE PERSONNES EMPLOYÉES AU 4E TRIMESTRE 2008-2009 NUMBER OF PERSONS EMPLOYED IN THE 4TH QUARTER 2008-2009	NOMBRE DE CHERCHEURS FORMÉS AU 4E TRIMESTRE 2008-2009 NUMBER OF SCIENTISTS TRAINED IN THE 4TH QUARTER 2008-2009	NOMBRE DE PUBLICATIONS ACCEPTÉES OU SOUMISES NUMBER OF PUBLICATIONS ACCEPTED OR SUBMITTED	NOMBRE DE CONFÉRENCES À TITRE DE CONFÉRENCIER NUMBER OF CONFERENCES AS SPEAKER	NOMBRE DE DÉCLARATIONS D'INVENTIONS OU DE BREVETS NUMBER OF DECLARATION OF INVENTIONS OR PATENTS	DATE DE DÉBUT DU PROJET PROJECT STARTING DATE
CONCOURS SANTÉ / HEALTH COMPETITION						
Barry Posner – Diabète de type 2 / T2DM	5	0	25	35	6	Octobre/October 2004
TOTAL	**5**	**0**	**25**	**35**	**6**	
CONCOURS III /COMPETITION III						
Sherif Abou Elela – FAEASI	17	4	7	18	3	Janvier/January 2006
Ken Dewar – Singe Vervet / Vervet Monkey	3	1	2	4	0	Janvier/January 2006
Thomas J. Hudson – GRID	37	10	38	12	2	Avril/April 2006
Guy Rouleau – S2D	22	1	1	12	1	Avril/April 2006
Jean-Claude Tardif – Pharmacogénomique / Pharmacogenomics	28	8	6	34	0	Avril/April 2006
Bartha Maria Knoppers – GPH	4	2	24	52	0	Janvier/January 2006
John MacKay – Arborea II	40	13	25	68	0	Avril/April 2006
TOTAL	**151**	**39**	**103**	**200**	**6**	
INITIATIVE DE CONSORTIUM INTERNATIONAL / INTERNATIONAL CONSORTIUM INITIATIVE						
Bartha Maria Knoppers / Thomas J. Hudson – P3G / CARTaGENE	31,66	18	28	50	0	Avril/April 2007
TOTAL	**31,66**	**18**	**28**	**50**	**0**	
CONCOURS PRIVAC / PRIVAC COMPETITION						
Daniel Lamarre / Sylvain Meloche – Plateforme ARNi	7	0	0	1	0	Janvier/January 2008
Rafick-Pierre Sékaly – Plateforme NIML	En démarrage					Mai/May 2009
Michel G. Bergeron – GPOCT	13	2	0	12	0	Janvier/January 2008
Michael Phillips / Jean-Claude Tardif – Via-PGX	7,5	0	0	0	0	Octobre/October 2007
TOTAL	27,5	2	0	13	0	
CONCOURS DÉVELOPPEMENT TECHNOLOGIQUE / TECHNOLOGICAL DEVELOPMENT COMPETITION						
Maryam Tabrizian – DevTab	9,2	8	7	9	1	Juillet/July 2008
Rafick-Pierre Sékaly / Ryan Brinkman – DevSek	4	1	1	0	0	Juillet/July 2008
TOTAL	13,2	9	8	9	1	
TOTAL CONCOURS (projets en cours) COMPETITION TOTAL (projects in progress)	**228,36**	**68**	**164**	**307**	**13**	

BILAN DES PROJETS TERMINÉS / ASSESSMENT OF COMPLETED PROJECTS

Mars / March 2009

	NOMBRE DE PERSONNES EMPLOYÉES EN ANNÉE/PERSONNE NUMBER OF PERSONS EMPLOYED IN YEAR/PERSON	NOMBRE DE CHERCHEURS FORMÉS EN ANNÉE/PERSONNE NUMBER OF SCIENTISTS TRAINED IN YEAR/PERSON	NOMBRE DE PUBLICATIONS ACCEPTÉES OU SOUMISES NUMBER OF PUBLICATIONS ACCEPTED OR SUBMITTED	NOMBRE DE CONFÉRENCES À TITRE DE CONFÉRENCIER NUMBER OF CONFERENCES AS SPEAKER	NOMBRE DE DÉCLARATIONS D'INVENTIONS OU DE BREVETS NUMBER OF DECLARATION OF INVENTIONS OR PATENTS	DURÉE DU PROJET PROJECT DURATION
CONCOURS I & II, SANTÉ / COMPETITIONS I & II, HEALTH						
Michel G. Bergeron – Technologies Theranostiques / Theranostic Technologies	118	25	25	58	11	3,25 ans/years
Deming Xu – Chimiogénomique / Chemogenomics	32	2	8	4	1	3 ans/years
Thomas J. Hudson – ARCTIC	42	6	19	15	9	3,25 ans/years
Franz Lang – PEP Québec	49	21	20	18	0	3,5 ans/years
Bussey / Michnick – Organismes modèles / Model Organisms	20	4	18	55	0	4 ans/years
John Bergeron – Protéomique / Proteomics	174	67	42	125	7	4 ans/years
Fernand Labrie – Atlas	347	120	49	29	2	5 ans/years
Bartha Maria Knoppers – GE^{3}LS	38	20	83	153	0	4 ans/years
Fathey Sarhan – Stress Abiotique Québec / Abiotic Stress Québec	82	28	11	17	0	4 ans/years
Thomas J. Hudson – Génétique régulatrice / Regulatory Genetics	117	27	16	51	6	4 ans/years
Rafick-Pierre Sékaly – S2K	194	79	17	150	6	4 ans/years
Mario Filion – IGWH	36	5	1	10	4	3 ans/years
Sherif Abou Elela – MoNa	51	8	6	9	2	3 ans/years
Adrian Tsang – Enzymes fongiques / Fungal enzymes	167	69	16	22	8	3 ans/years
Benoît Coulombe – Réseau de régulation / Regulatory Networks	189	63	15	111	0	3,5 ans/years
John MacKay – Arborea I	98	31	23	63	2	3,5 ans/years
Thomas J. Hudson – Haplotype	34	2	14	87	1	3 ans/years
Emil Skamene – Souris congéniques / Congenic Mice	60	13	2	11	3	4,25 ans/years
Guy Rouleau – Canaux ioniques / Ionic Channels	40	5	0	16	3	4,25 ans/years
Terry Roemer – Candida albicans	51	0	2	3	3	3 ans/years
TOTAL CONCOURS TERMINÉS / TOTAL COMPLETED PROJECTS	**1939**	**595**	**387**	**1007**	**68**	